Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q1 FY27 results · Apr–Jun 2026
Neuland Laboratories reported revenue from operations of ₹641.58 crore (up 119.2% from Q1 FY26) and net profit of ₹147.67 crore (up 962.4% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 641.58 | 292.75 | +119.2% | 776.25 | −17.3% |
| Other income | 8.49 | 7.86 | +8.1% | 12.46 | −31.8% |
| Total income | 650.07 | 300.61 | +116.3% | 788.71 | −17.6% |
| Profit before tax | 197.85 | 17.57 | 11x | 287.49 | −31.2% |
| Net profit for the period | 147.67 | 13.90 | +962.4% | 212.67 | −30.6% |
| EPS, basic (₹) | 115.10 | 10.83 | +962.8% | 165.76 | −30.6% |
| Net margin (%) | 23.0 | 4.7 | 27.4 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 641.58 | 292.75 | +119.2% | 776.25 | −17.3% |
| Other income | 8.49 | 7.86 | +8.1% | 12.46 | −31.8% |
| Total income | 650.07 | 300.61 | +116.3% | 788.71 | −17.6% |
| Profit before tax | 197.54 | 17.38 | 11x | 287.04 | −31.2% |
| Net profit for the period | 147.36 | 13.71 | +975.0% | 212.52 | −30.7% |
| EPS, basic (₹) | 114.86 | 10.68 | +975.5% | 165.65 | −30.7% |
| Net margin (%) | 23.0 | 4.7 | 27.4 |
Consolidated
- Filed with BSE
- 05 Aug 2026, 18:03 IST
- Board meeting
- 05 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Aug 2026, 18:03 IST
- Board meeting
- 05 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE